Psyence BioMed agrees to invest up to USD 5 million in PsyLabs via share subscription
Bitget2026/09/23 11:06- Psyence Biomedical agreed to invest up to USD 5 million in PsyLabs, with USD 2.4 million irrevocably committed in its current financing round.
- Remaining up to USD 2.6 million set as a backstop subscription in up to two USD 1.3 million tranches, subject to milestones.
- Value-matched share exchange set at about USD 9 million each side, pending approvals, with a Nov. 30, 2026 termination date.
- Psyence BioMed to issue 1,497,500 common shares to PsyLabs at a deemed price of USD 6 per share.
- PsyLabs to issue 3,473 ordinary shares to Psyence BioMed, implying a PsyLabs equity valuation of USD 60 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
